List of APIs/Active Pharmaceutical Ingredients Companies in Germany - 9

BELANO - The Microbiome Company Die Erforschung des menschlichen Mikrobioms hat in den letzten Jahren zu wegweisenden Erkenntnissen geführt. Das Verständnis der Wechselwirkung zwischen Bakterienwelt um uns herum und unseren Körperfunktionen führt zu innovativen Therapieansätzen. Aus dieser Forschung sind bei BELANO mikrobiotische Wirkstoffe entstanden, die in Produkten in den Bereichen Derma & Kosmetik, Hals & Rachen, Mund & Magen und Wundversorgung & Hygiene eingesetzt werden.

ChemCon GmbH - Your Good Manufacturing Partner! ChemCon is a contract development and manufacturing organization (CDMO) located in Freiburg, Germany. We manufacture drug substances (injectable, ophthalmic, oral, topic grade) and ultra-pure chemicals to your specifications. With multidisciplinary expertise we can meet your individual demands for small-molecule organic APIs, inorganic compounds, polymers, and highly potent or controlled substances. ChemCon’s facilities are optimized for the production of small to medium quantities (g to multi 100 kg per year). This is particularly interesting if you are sourcing APIs for clinical trials or commercial applications (i.e., orphan diseases, oncology, or emergency care) with a low annual demand. We also manufacture excipients, provocation substances, dietary trace elements, diagnostics, delivery agents, or reference standards. Your project will be under one roof from synthesis & process development/establishment all the way to commercial cGMP manufacturing, including full documentation, quality control and regulatory support. We also offer external analytical services, independent from production services. ChemCon looks back on an outstanding inspection history by both the FDA and European health authorities. Impressum: ChemCon GmbH, Engesserstr. 4b, 79108 Freiburg i.Br. Phone.: +49 (0)761-5597-0; E-Mail: Info@chemcon.com CEO/President: Dr. Raphael Vogler Commercial register: HRB 5973 Court of registration: Freiburg VAT Reg. No: DE812753447

At ColVisTec, we work with the world's leading manufacturers in the paint, pharmaceutical, plastics, and chemical industries. Our team of highly knowledgeable engineers and scientists support them with a reliable and industry-ready inline UV-Vis spectroscopy.​ ​ By adding inline UV-Vis spectrophotometry devices onto the assembly line, we can measure the production output in real-time. In addition, it opens fantastic opportunities for productivity as well as quality gains, leading to a huge stand-alone benefit for your factory when implemented into the context of digitalized manufacturing: Industry 4.0. Our technology can be customized for a wide variety of processes, allowing flexible hardware configurations, offering data output in different formats, and excellent integration with the software solutions already in place. We take pride in our extensive customer support and provide a full menu of training options to secure a smooth transition from off-line measurement to fully automated inline solutions. ​ From our headquarters in Berlin, Germany, we support our product line worldwide and work in close cooperation with other process machinery manufacturers to provide complete solutions when customers are in the market for new plants. Most often our technology is fitted to the existing manufacturing facilities, boosting their productivity and quality. We don’t see ourselves as suppliers of hardware, our aim is to provide unique solutions that are specifically required by your process. ​ Our company was founded in 2009 and is now co-funded by the Horizon 2020 program of the European Union.

CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com

Evonik is one of the world’s leading specialty chemicals companies. While we don’t produce electric cars, aircraft, medications or 3D printers, Evonik is part and parcel of these and many other end products. That’s because we contribute the small things that make a big difference. We make electric car batteries perform better, aircraft greener, medications more effective and 3D printers more efficient. In short: We think beyond the bounds of chemistry to make the world a better place. Today and tomorrow. We are an international group with a workforce of over 32,000 people spread across more than one hundred locations. Our daily work is shaped by global concerns, such as sustainability, diversity and digitalization. In all our business decisions, we take the present and future generations into consideration. After all, being ready for tomorrow is our business. Interested in joining our global team? Our wide range of opportunities extends from creative and innovative research through international management all the way to production. Whether you’re studying, starting out in your career or a seasoned professional, come help us make the world a better place. For more information about careers at Evonik, go to: www.careers.evonik.com. #HumanChemistry Find our netiquette on: www.evonik.com/netiquette

Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Former clinical assets MESUPRON® and REDECTANE® have been partnered. Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first water-free technology worldwide for ophthalmology products. With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye disease. With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye disease. NOV03 and CyclASol® are the two late stage development compounds. NOV03 is the first drug developed to treat evaporative DED associated with meibomian gland dysfunction in a highly effective way. CyclASol®, an ophthalmic solution of 0.1% cyclosporine A in EyeSol®, is an anti-inflammatory and immunomodulating drug for the treatment of aqueous deficient DED. Both compounds have shown superior clinical benefit, with an onset of action and an excellent tolerability profile. NovaTears® water-free eye drops for dry eye disease have CE certification and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies.

Phyton Biotech is the world's leader in pharmaceutical plant cell fermentation (PCF®) technology. A global supplier of high quality oncology actives via PCF, our products are registered in every major country in the world. With state-of-the-art facilities near Hamburg and Vancouver, we also offer comprehensive development services via PCF for plant-based actives, complex small molecules, and a variety of products used in the treatment of cancer and other serious illnesses.

Our mission: Develop and manufacture highly effective wound dressings for acute wounds suchs as burns, abrasions, lacerations, skin graft donor sites chronic wounds Our main focus is on burn wounds Products & solutions for medical personnel (wound dressings, cooling vests) Our high quality products are developed & manufactured in Germany Strong international network of burn and plastic surgeons Our products distributed in more than 25 countries Our R&D: New projects in close collaboration with leading specialists